SNORD16 and breast cancer: SNORD16, SNORA73B, SCARNA4, and SNORD49B were found to be upregulated in both breast cancer and early-stage breast cancer, and have emerged as potential biomarkers for the diagnosis of these conditions (Li et al. 2024).